
## Maxwell Korang-Yeboah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1267269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews, 2017, 108, 39-50.	13.7	554
2	Comparative Evaluation of Flow for Pharmaceutical Powders and Granules. AAPS PharmSciTech, 2008, 9, 250-258.	3.3	326
3	Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman design. International Journal of Pharmaceutics, 2010, 389, 186-194.	5.2	138
4	A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. International Journal of Pharmaceutics, 2011, 419, 52-59.	5.2	125
5	Quality by design: Understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box–Behnken design and desirability function. International Journal of Pharmaceutics, 2007, 332, 55-63.	5.2	118
6	Selective laser sintering 3D printing – an overview of the technology and pharmaceutical applications. Drug Development and Industrial Pharmacy, 2020, 46, 869-877.	2.0	116
7	Physico-mechanical and Stability Evaluation of Carbamazepine Cocrystal with Nicotinamide. AAPS PharmSciTech, 2011, 12, 693-704.	3.3	107
8	Predicting hydrophilic drug encapsulation inside unilamellar liposomes. International Journal of Pharmaceutics, 2012, 423, 410-418.	5.2	93
9	Additive Manufacturing with 3D Printing: Progress from Bench to Bedside. AAPS Journal, 2018, 20, 101.	4.4	90
10	A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. International Journal of Pharmaceutics, 2012, 426, 211-218.	5.2	80
11	Understanding the effects of formulation and process variables on the printlets quality manufactured by selective laser sintering 3D printing. International Journal of Pharmaceutics, 2019, 570, 118651.	5.2	72
12	Quality by design: Impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody. International Journal of Pharmaceutics, 2012, 438, 167-175.	5.2	69
13	Tablet Splitting of a Narrow Therapeutic Index Drug: A Case with Levothyroxine Sodium. AAPS PharmSciTech, 2010, 11, 1359-1367.	3.3	64
14	Development of performance matrix for generic product equivalence of acyclovir topical creams. International Journal of Pharmaceutics, 2014, 475, 110-122.	5.2	64
15	Development and validation of in vitro–in vivo correlation ( IVIVC ) for estradiol transdermal drug delivery systems. Journal of Controlled Release, 2015, 210, 58-66.	9.9	61
16	Defining Patient Centric Pharmaceutical Drug Product Design. AAPS Journal, 2016, 18, 1047-1055.	4.4	61
17	Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. International Journal of Pharmaceutics, 2015, 493, 412-425.	5.2	54
18	Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. Pharmaceutical Research, 1993, 10, 1191-1199.	3.5	51

#	Article	IF	CITATIONS
19	3D-printing of lopinavir printlets by selective laser sintering and quantification of crystalline fraction by XRPD-chemometric models. International Journal of Pharmaceutics, 2021, 592, 120059.	5.2	50
20	Near-Infrared Investigations of Novel Anti-HIV Tenofovir Liposomes. AAPS Journal, 2010, 12, 202-214.	4.4	46
21	Influence of Formulation and Processing Factors on Stability of Levothyroxine Sodium Pentahydrate. AAPS PharmSciTech, 2010, 11, 818-825.	3.3	46
22	Formulation Optimization of Selective Laser Sintering 3D-Printed Tablets of Clindamycin Palmitate Hydrochloride by Response Surface Methodology. AAPS PharmSciTech, 2020, 21, 232.	3.3	44
23	Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. International Journal of Pharmaceutics, 2016, 502, 138-150.	5.2	41
24	Kinetics of drug release from ointments: Role of transient-boundary layer. International Journal of Pharmaceutics, 2015, 494, 31-39.	5.2	37
25	Improvement of Physicochemical Properties of an Antiepileptic Drug by Salt Engineering. AAPS PharmSciTech, 2012, 13, 793-801.	3.3	35
26	Disintegration of Highly Soluble Immediate Release Tablets: A Surrogate for Dissolution. AAPS PharmSciTech, 2009, 10, 495-499.	3.3	33
27	Chemometric Model Development and Comparison of Raman and 13C Solid-State Nuclear Magnetic Resonance–Chemometric Methods for Quantification of Crystalline/Amorphous Warfarin Sodium Fraction in the Formulations. Journal of Pharmaceutical Sciences, 2015, 104, 2550-2558.	3.3	33
28	Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. International Journal of Pharmaceutics, 2015, 495, 783-791.	5.2	33
29	Online Monitoring of PLGA Microparticles Formation Using Lasentec Focused Beam Reflectance (FBRM) and Particle Video Microscope (PVM). AAPS Journal, 2010, 12, 254-262.	4.4	31
30	Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin. Pharmaceutical Development and Technology, 2012, 17, 457-465.	2.4	29
31	Risk based in vitro performance assessment of extended release abuse deterrent formulations. International Journal of Pharmaceutics, 2016, 500, 255-267.	5.2	28
32	Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets. International Journal of Pharmaceutics, 2017, 517, 303-311.	5.2	28
33	Chemometric Methods for the Quantification of Crystalline Tacrolimus in Solid Dispersion by Powder Xâ€Ray Diffractrometry. Journal of Pharmaceutical Sciences, 2014, 103, 2819-2828.	3.3	27
34	Complexation of risperidone with a taste-masking resin: Novel application of near infra-red and chemical imaging to evaluate complexes. Pharmaceutical Development and Technology, 2009, 14, 409-421.	2.4	26
35	Tannate complexes of antihistaminic drug: Sustained release and taste masking approaches. International Journal of Pharmaceutics, 2012, 422, 91-100.	5.2	24
36	Effect of chiral enhancers on the permeability of optically active and racemic metoprolol across hairless mouse skin. , 1999, 11, 536-540.		23

#	Article	IF	CITATIONS
37	Formulation and Evaluation of a Protein-loaded Solid Dispersions by Non-destructive Methods. AAPS Journal, 2010, 12, 158-170.	4.4	21
38	An Integrated Process Analytical Technology (PAT) Approach to Monitoring the Effect of Supercooling on Lyophilization Product and Process Parameters of Model Monoclonal Antibody Formulations. Journal of Pharmaceutical Sciences, 2014, 103, 2042-2052.	3.3	21
39	Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product. International Journal of Pharmaceutics, 2015, 495, 19-30.	5.2	21
40	Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium. International Journal of Pharmaceutics, 2018, 550, 290-299.	5.2	21
41	Quantitative estimation of phenytoin sodium disproportionation in the formulations using vibration spectroscopies and multivariate methodologies. International Journal of Pharmaceutics, 2018, 539, 65-74.	5.2	20
42	Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium. Journal of Pharmaceutical Sciences, 2015, 104, 4232-4240.	3.3	19
43	Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, 29-38.	1.2	19
44	Inhibitor of Differentiation 4 (ID4) Inactivation Promotes De Novo Steroidogenesis and Castration-Resistant Prostate Cancer. Molecular Endocrinology, 2014, 28, 1239-1253.	3.7	18
45	Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations. International Journal of Pharmaceutics, 2015, 490, 341-350.	5.2	18
46	Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products. International Journal of Pharmaceutics, 2015, 493, 1-6.	5.2	18
47	Blend of cellulose ester and enteric polymers for delayed and enteric coating of core tablets of hydrophilic and hydrophobic drugs. International Journal of Pharmaceutics, 2019, 567, 118462.	5.2	18
48	Application of NIR chemometric methods for quantification of the crystalline fraction of warfarin sodium in drug product. Drug Development and Industrial Pharmacy, 2016, 42, 584-594.	2.0	17
49	Statistical Optimization of Ketoprofen-Eudragit® S100 Coprecipitates to Obtain Controlled-Release Tablets. Drug Development and Industrial Pharmacy, 1996, 22, 135-141.	2.0	16
50	Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. International Journal of Pharmaceutics, 2014, 475, 462-470.	5.2	16
51	Chemometric Models for Quantification of Carbamazepine Anhydrous and Dihydrate Forms in the Formulation. Journal of Pharmaceutical Sciences, 2019, 108, 1211-1219.	3.3	16
52	Printing of personalized medication using binder jetting 3D printer. , 2020, , 473-481.		16
53	Oseltamivir Phosphate–Amberlite™ IRP 64 Ionic Complex for Taste Masking: Preparation and Chemometric Evaluation. Journal of Pharmaceutical Sciences, 2013, 102, 1800-1812.	3.3	15
54	Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration. International Journal of Pharmaceutics, 2014, 473, 545-551.	5.2	15

#	Article	IF	CITATIONS
55	Polycaprolactone/maltodextrin nanocarrier for intracellular drug delivery: formulation, uptake mechanism, internalization kinetics, and subcellular localization. International Journal of Nanomedicine, 2015, 10, 4763.	6.7	15
56	Fractionated charge variants of biosimilars: A review of separation methods, structural and functional analysis. Analytica Chimica Acta, 2021, 1152, 238189.	5.4	15
57	Aqueous-Based Polymeric Dispersion: Face-Centered Cubic Design for the Development of Atenolol Gastrointestinal Therapeutic System. Pharmaceutical Development and Technology, 1998, 3, 423-432.	2.4	14
58	Spectroscopic-Based Chemometric Models for Quantifying Low Levels of Solid-State Transitions in Extended Release Theophylline Formulations. Journal of Pharmaceutical Sciences, 2016, 105, 97-105.	3.3	14
59	Complexation between risperidone and amberlite resin by various methods of preparation and binding study. Drug Development and Industrial Pharmacy, 2009, 35, 1409-1418.	2.0	13
60	Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations. International Journal of Pharmaceutics, 2016, 499, 20-28.	5.2	13
61	Very-Rapidly Dissolving Printlets of Isoniazid Manufactured by SLS 3D Printing: In Vitro and In Vivo Characterization. Molecular Pharmaceutics, 2022, 19, 2937-2949.	4.6	13
62	Challenges of pediatric formulations: A FDA science perspective. International Journal of Pharmaceutics, 2013, 457, 346-348.	5.2	12
63	Ultra-long acting prodrug of dolutegravir and delivery system – Physicochemical, pharmacokinetic and formulation characterizations. International Journal of Pharmaceutics, 2021, 607, 120889.	5.2	12
64	Quality and In-Use Stability Comparison of Brand and Generics of Extended-Release Phenytoin Sodium Capsules. Journal of Pharmaceutical Sciences, 2019, 108, 1808-1817.	3.3	11
65	Development of Methamphetamine Abuse–Deterrent Formulations Using Sucrose Acetate Isobutyrate. Journal of Pharmaceutical Sciences, 2020, 109, 1338-1346.	3.3	11
66	InÂVitro Testing of Sunscreens for Dermal Absorption: A Platform for Product Selection for Maximal Usage Clinical Trials. Journal of Investigative Dermatology, 2020, 140, 2487-2495.	0.7	11
67	Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth. Oncotarget, 2016, 7, 68072-68085.	1.8	11
68	Difference in the Lubrication Efficiency of Bovine and Vegetable-Derived Magnesium Stearate During Tabletting. AAPS PharmSciTech, 2009, 10, 500-504.	3.3	10
69	Development and Validation of a HPLC Method for Dissolution and Stability Assay of Liquid-Filled Cyclosporine Capsule Drug Products. AAPS PharmSciTech, 2013, 14, 959-967.	3.3	10
70	Quality attributes and evaluation of pharmaceutical glass containers for parenterals. International Journal of Pharmaceutics, 2019, 568, 118510.	5.2	10
71	Quantitative evaluation of the thallium binding of soluble and insoluble Prussian blue hexacyanoferrate analogs: A scientific comparison based on their critical quality attributes. International Journal of Pharmaceutics, 2019, 569, 118600.	5.2	10
72	Effect of Additives on the Diffusion of Ketoprofen Through Human Skin. Drug Development and Industrial Pharmacy, 1996, 22, 471-474.	2.0	9

#	Article	IF	CITATIONS
73	Hunter screening design to understand the product variability of solid dispersion formulation of a peptide antibiotic. International Journal of Pharmaceutics, 2013, 456, 572-582.	5.2	9
74	Development and Validation of a Discriminatory Dissolution Method for Rifaximin Products. Journal of Pharmaceutical Sciences, 2019, 108, 2112-2118.	3.3	9
75	Development of stable amorphous solid dispersion and quantification of crystalline fraction of lopinavir by spectroscopic-chemometric methods. International Journal of Pharmaceutics, 2021, 602, 120657.	5.2	9
76	Influence of psychostimulants and opioids on epigenetic modification of class III histone deacetylase (HDAC)-sirtuins in glial cells. Scientific Reports, 2021, 11, 21335.	3.3	9
77	Intraocular Pressure-Lowering Activity and In Vivo Disposition of Dipivalyl Terbutalone in Rabbits. Drug Development and Industrial Pharmacy, 2001, 27, 137-141.	2.0	8
78	Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate. AAPS PharmSciTech, 2020, 21, 99.	3.3	8
79	Chemical Delivery Systems: Evaluation of Physicochemical Properties and Enzymatic Stability of Phenylephrone Derivatives. Pharmaceutical Development and Technology, 1999, 4, 189-198.	2.4	7
80	Cataplasm-Based Controlled Drug Delivery: Development and Optimization of a Novel Formulation. Drug Development and Industrial Pharmacy, 1999, 25, 659-665.	2.0	7
81	Focused beam reflectance measurement to monitor nimodipine precipitation process. International Journal of Pharmaceutics, 2013, 456, 353-356.	5.2	6
82	Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin. International Journal of Pharmaceutics, 2015, 481, 104-113.	5.2	6
83	Comparison of Univariate and Multivariate Models of 13C SSNMR and XRPD Techniques for Quantification of Nimodipine Polymorphs. AAPS PharmSciTech, 2015, 16, 1368-1376.	3.3	6
84	Application of Optical Coherence Tomography Freeze-Drying Microscopy for Designing Lyophilization Process and Its Impact on Process Efficiency and Product Quality. AAPS PharmSciTech, 2018, 19, 448-459.	3.3	6
85	Studying effect of glyceryl palmitostearate amount, manufacturing method and stability on polymorphic transformation and dissolution of rifaximin tablets. International Journal of Pharmaceutics, 2020, 589, 119785.	5.2	6
86	Effects of Diluents on Physical and Chemical Stability of Phenytoin and Phenytoin Sodium. AAPS PharmSciTech, 2020, 21, 104.	3.3	6
87	Preparation and characterization of dicarboxylic acids salt of aripiprazole with enhanced physicochemical properties. Pharmaceutical Development and Technology, 2021, 26, 455-463.	2.4	6
88	Ibuprofen Release from Beads Coated with an Experimental Latex: Effect of Certain Variables. Drug Development and Industrial Pharmacy, 1997, 23, 145-155.	2.0	5
89	Application of chemometric methods to differential scanning calorimeter (DSC) to estimate nimodipine polymorphs from cosolvent system. Drug Development and Industrial Pharmacy, 2015, 41, 995-999.	2.0	5
90	Univariate and Multivariate Models for Determination of Prasugrel Base in the Formulation of Prasugrel Hydrochloride Using XRPD Method. Journal of Pharmaceutical Sciences, 2019, 108, 3575-3581.	3.3	5

#	Article	IF	CITATIONS
91	Application of salt engineering to reduce/mask bitter taste of clindamycin. Drug Development and Industrial Pharmacy, 2019, 45, 1871-1878.	2.0	5
92	Salt Engineering of Aripiprazole with Polycarboxylic Acids to Improve Physicochemical Properties. AAPS PharmSciTech, 2021, 22, 31.	3.3	5
93	HIV-1 Tat and cocaine impact astrocytic energy reservoir influence on miRNA epigenetic regulation. Genomics, 2021, 113, 3461-3475.	2.9	5
94	Development of a Multivariate Predictive Dissolution Model for Tablets Coated with Cellulose Ester Blends. Pharmaceuticals, 2020, 13, 311.	3.8	4
95	Effect of formulation and peptide folding on the fibrillar aggregation, gelation, and oxidation of a therapeutic peptide. International Journal of Pharmaceutics, 2021, 604, 120677.	5.2	4
96	In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery. Journal of Pharmaceutical Sciences, 2022, 111, 2312-2321.	3.3	4
97	An Enteric Dualâ€Controlled Gastrointestinal Therapeutic System of Salmon Calcitoninâ€I: Preparation, Characterization, and Preclinical Bioavailability in Rats. Clinical Research and Regulatory Affairs, 2004, 21, 81-96.	2.1	3
98	A headspace-gas chromatography method for isopropanol determination in warfarin sodium products as a measure of drug crystallinity. Acta Pharmaceutica, 2018, 68, 31-46.	2.0	3
99	Coating characterization by hyperspectroscopy and predictive dissolution models of tablets coated with blends of cellulose acetate and cellulose acetate phthalate. AAPS PharmSciTech, 2021, 22, 122.	3.3	3
100	Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs. AAPS PharmSciTech, 2022, 23, 35.	3.3	3
101	FDA: Contribution to developing pediatric formulations and transatlantic collaboration. International Journal of Pharmaceutics, 2012, 435, 146-148.	5.2	2
102	Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products. International Journal of Pharmaceutics, 2020, 575, 118909.	5.2	2
103	HIV-1 Tat and cocaine coexposure impacts piRNAs to affect astrocyte energy metabolism. Epigenomics, 2022, 14, 261-278.	2.1	2
104	FDA Analysis of Atorvastatin Products Refutes Report of Methyl Ester Impurities. Therapeutic Innovation and Regulatory Science, 2014, 48, 554-556.	1.6	1
105	Potential Application of USP Paddle and Basket Dissolution Methods in Discriminating for Portioned Moist Snuff and Snus Smokeless Tobacco Products. AAPS PharmSciTech, 2021, 22, 51.	3.3	1
106	Development and Validation of a Discriminatory Dissolution Method for Portioned Moist Snuff and Snus. Journal of Pharmaceutical Sciences, 2021, , .	3.3	1
107	Use of SIRC Rabbit Corneal Cell Lines Grown on Polycarbonate- or Polyester-Based Filters to Assess the In Vitro Corneal Transport/Toxicity Screening Using Pilocarpine With or Without Benzalkonium Chloride. Cutaneous and Ocular Toxicology, 2003, 22, 101-114.	0.3	0